scholarly journals 964: EVALUATION OF DEXMEDETOMIDINE WITHDRAWAL AND MANAGEMENT AFTER PROLONGED INFUSION

2021 ◽  
Vol 50 (1) ◽  
pp. 479-479
Author(s):  
Christine Kim ◽  
Kaitlin Crowley ◽  
Kevin McLaughlin ◽  
Natasha Romero
Keyword(s):  
Prolonged Infusion

ELIMINATION OF INFUSED ARGININE-VASOPRESSIN AND ITS LONG-ACTING DEAMINATED ANALOGUE IN RATS

1978 ◽  
Vol 78 (2) ◽  
pp. 179-186 ◽  
Author(s):  
DIANA GAZIS ◽  
W. H. SAWYER
Keyword(s):  
Arginine Vasopressin ◽  
Plasma Concentrations ◽  
Metabolic Clearance ◽  
Prolonged Infusion ◽  
Exponential Functions ◽  
Antidiuretic Effect ◽  
Long Acting ◽  
Deamino Arginine Vasopressin

SUMMARY Arginine-vasopressin (AVP) and deamino-arginine-vasopressin (dAVP) were infused into rats. When the concentrations of the two peptides were steady, the rate of clearance of AVP from the plasma was six times the rate of clearance of dAVP. Only 6% of the infused AVP was excreted unchanged in the urine, whereas approximately 100% of the dAVP was excreted. When the infusions were stopped, AVP disappeared from the plasma much more rapidly than dAVP. The plasma concentrations of the two peptides did not decay as simple exponential functions, suggesting that both AVP and dAVP entered a slowly exchanging compartment or compartments during prolonged infusion. These differences in the metabolic clearance of AVP and dAVP may well explain the prolonged antidiuretic effect of dAVP in rats.

Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study

2005 ◽  
Vol 131 (9) ◽  
pp. 568-574 ◽  
Author(s):  
Peter Schmid ◽  
Volker Heilmann ◽  
Carsten-Oliver Schulz ◽  
Annette Dieing ◽  
Silvia Lehenbauer-Dehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Prolonged Infusion

scholarly journals In VitroPharmacodynamics of Simulated Pulmonary Exposures of Tigecycline Alone and in Combination againstKlebsiella pneumoniaeIsolates Producing a KPC Carbapenemase

2011 ◽  
Vol 55 (4) ◽  
pp. 1420-1427 ◽  
Author(s):  
Dora E. Wiskirchen ◽  
Pornpan Koomanachai ◽  
Anthony M. Nicasio ◽  
David P. Nicolau ◽  
Joseph L. Kuti
Keyword(s):  
Multidrug Resistant ◽  
Pharmacodynamic Model ◽  
High Dose ◽  
Prolonged Infusion ◽  
Bacterial Killing ◽  
Epithelial Lining Fluid ◽  
Multidrug Resistant Organisms ◽  
Time Kill ◽  
Additional Reduction

ABSTRACTMultidrug-resistantKlebsiella pneumoniaestrains that produce a serine carbapenemase (KPC) are emerging worldwide, with few therapeutic options that retain consistent susceptibility. The objective of this study was to determine the effect of combination therapy with tigecycline versus tigecycline alone against KPC-producing isolates (KPC isolates). Anin vitropharmacodynamic model was used to simulate adult steady-state epithelial lining fluid concentrations of tigecycline (50 mg every 12 h) given alone and in combination with either meropenem (2 g by 3-hour infusion every 8 h) or rifampin (600 mg every 12 h). Five KPC isolates with various phenotypic profiles were exposed over 48 h. Time-kill curves were constructed, and the areas under the bacterial killing and regrowth curves (AUBCs) were calculated. No regimens tested were able to maintain bactericidal reductions in CFU over 48 h. The AUBCs for tigecycline and meropenem monotherapies at 48 h ranged from 375.37 to 388.11 and from 348.62 to 383.83 (CFU-h/ml), respectively. The combination of tigecycline plus meropenem significantly reduced the AUBCs at 24 and 48 h for isolates with tigecycline MICs of ≤2 μg/ml and meropenem MICs of ≤16 μg/ml (P< 0.001) but added no additional activity when the meropenem MIC was 64 μg/ml (P= 0.5). Rifampin provided no additional reduction in CFU or AUBC over tigecycline alone (P= 0.837). The combination of tigecycline with high-dose, prolonged-infusion meropenem warrants further study as a potential treatment option for these multidrug-resistant organisms.

scholarly journals Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study

2021 ◽  
pp. 106289
Author(s):  
Albrecht Eisert ◽  
Christian Lanckohr ◽  
Janina Frey ◽  
Otto Frey ◽  
Sebastian G Wicha ◽  
...  
Keyword(s):  
Septic Shock ◽  
Pilot Study ◽  
Prolonged Infusion ◽  
Dosing Regimens

ViVACCy—A Drug Schedule Based on G2 Blockade and Prolonged Infusion of Multiple Tubulin-Binding Agents A Pilot Study

Cancer ◽  
1990 ◽  
Vol 66 (3) ◽  
pp. 411-417
Author(s):  
Stanley E. Shackney ◽  
Reginald P. Pugh ◽  
Bernard L. Zidar ◽  
Robert N. Raju ◽  
Sheryl R. Simon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Prolonged Infusion ◽  
Tubulin Binding ◽  
Binding Agents

scholarly journals Influence of β-Lactam Infusion Strategy on Acute Kidney Injury

2017 ◽  
Vol 61 (10) ◽  
Author(s):  
Sarah E. Cotner ◽  
W. Cliff Rutter ◽  
Donna R. Burgess ◽  
Katie L. Wallace ◽  
Craig A. Martin ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Medical Center ◽  
Academic Medical Center ◽  
Kidney Injury ◽  
Intermittent Infusion ◽  
Prolonged Infusion ◽  
Infusion Group ◽  
Academic Medical ◽  
Baseline Creatinine ◽  
End Stage

ABSTRACT Limited literature is available assessing nephrotoxicity with prolonged β-lactam infusions. This study compared the incidence of acute kidney injury (AKI) associated with a prolonged β-lactam infusion or an intermittent infusion. This was a retrospective, matched-cohort study at an academic medical center from July 2006 to September 2015. Adult patients who received piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) for at least 48 h were evaluated. Patients were excluded for preexisting renal dysfunction or pregnancy. The primary outcome was difference in incidence of AKI evaluated using the RIFLE (risk, injury, failure, loss, and end-stage) criteria. Patients in the intermittent group were matched 3:1 to patients in the prolonged-infusion group based on the following: β-lactam agent, age, gender, Charlson comorbidity index, baseline creatinine clearance, hypotension, receipt of vancomycin, and treatment in an intensive care unit. A total of 2,390 patients were included in the matched analysis, with 1,700 receiving intermittent infusions and 690 receiving prolonged infusion. The incidence of AKI was similar in the prolonged-infusion group to that in the intermittent-infusion group (21.6% versus 18.6%; P = 0.1). After multivariate regression, prolonged infusion was not associated with increased odds of AKI (odds ratio [OR], 1.07; 95% confidence interval [95% CI], 0.83 to 1.39). Independent predictors of AKI included TZP therapy, concomitant nephrotoxins, hypotension, and heart failure. Although AKIs were numerically more common in patients receiving prolonged β-lactam infusions than those receiving intermittent infusions, prolonged infusion was not an independent risk factor for AKI.

Sign in / Sign up

Export Citation Format

Share Document